HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a $32.00 price target on the biotechnology company’s stock. A number of other research analysts have also weighed in on IOVA. The Goldman Sachs Group […]

Related Keywords

United States , Chicago , Illinois , American , Piper Sandler , Iovance Biotherapeutics , Iovance Biotherapeutics Inc , Wells Fargo Company , Raymond James Associates , Chicago Partners Investment Group , Goldman Sachs Group , American International Group Inc , Free Report , Moderate Buy , Get Free Report , Fire Capital , Partners Investment Group , International Group , Raymond James ,